Skip to main content

Table 1 Demographic and clinical features of the MSA patients with and without camptocormia

From: Camptocormia in patients with multiple system atrophy at different disease durations: frequency and related factors

Variables Total With camptocormia Without camptocormia P value
Number 716 90 (12.6%) 626 (87.4%)
Diagnosis (MSA-P/MSA-C) 352/364 60/30 292/334 < 0.001*
Sex (male/female) 405/311 46/44 359/267 0.264
Age 60.18 ± 8.99 63.73 ± 7.91 59.67 ± 9.03 < 0.001*
Age of onset 57.54 ± 8.94 60.53 ± 7.81 57.11 ± 9.02 0.001*
Disease duration 2.59 ± 1.69 3.18 ± 1.67 2.50 ± 1.67 < 0.001*
Educational year 9.46 ± 3.92 9.21 ± 4.16 9.49 ± 3.89 0.522
Onset symptoms     
Autonomic symptom 247 28 219 0.005*
Cerebellar symptom 198 15 183
Parkinsonism symptom 271 47 224
UMSARS-I 14.30 ± 6.68 17.97 ± 7.43 13.77 ± 6.40 < 0.001*#
UMSARS-II 16.98 ± 6.95 21.89 ± 7.60 16.28 ± 6.56 < 0.001*#
UMSARS-IV 2.00 ± 0.96 2.68 ± 1.17 1.90 ± 0.88 < 0.001*#
Total UMSARS score 31.28 ± 12.80 39.86 ± 14.22 30.04 ± 12.11 < 0.001*#
OH (yes/no) 198/518 28/62 170/456 0.433
Total score of FAB 14.32 ± 2.96 13.52 ± 3.47 14.44 ± 2.87 0.006*
Total MOCA score 21.57 ± 5.06 20.71 ± 6.00 21.70 ± 4.91 0.084
HDRS score 11.47 ± 8.03 13.57 ± 9.09 11.16 ± 7.83 0.008*
HARS score 9.52 ± 7.02 10.11 ± 7.27 9.43 ± 6.98 0.392
LEDD (mg/day) 137.40 ± 243.00 209.58 ± 270.48 127.02 ± 237.22 0.001*
  1. MSA multiple system atrophy, MSA-P multiple system atrophy with predominately parkinsonism, MSA-C multiple system atrophy with predominately cerebellar ataxia, UMSARS unified multiple system atrophy rating scale, OH orthostatic hypotension, FAB frontal lobe battery, MoCA Montreal cognitive assessment, HDRS Hamilton depression rating scale, HARS Hamilton anxiety rating scale, LEDD levodopa equivalent daily dose
  2. *: significant difference after adjusting by false discovery rate
  3. #: after adjusting for age of onset and disease duration